EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

•MRD-negativity at 12 months reduced the risk of progression; the treatment effect on MRD was correlated with the treatment effect on PFS.•MRD-negativity is reasonably likely to eventually demonstrate a treatment effect on PFS.